These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3981428)

  • 1. Novel method of calculating absolute bioavailability in nonlinear pharmacokinetics.
    Veng-Pedersen P
    J Pharm Sci; 1985 Jan; 74(1):90-3. PubMed ID: 3981428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis.
    Veng-Pedersen P
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):627-48. PubMed ID: 6533297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-independent steady-state plasma level predictions in autonomic nonlinear pharmacokinetics I: Derivation and theoretical analysis.
    Veng-Pedersen P
    J Pharm Sci; 1984 Jun; 73(6):761-5. PubMed ID: 6737260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonlinear physiologic pharmacokinetic model: I. Steady-state.
    Wagner JG; Szpunar GJ; Ferry JJ
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):73-92. PubMed ID: 4020623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):834-48. PubMed ID: 16493592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.
    Gillespie WR; Veng-Pedersen P
    J Pharmacokinet Biopharm; 1985 Aug; 13(4):441-51. PubMed ID: 4087171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifications of the Method for Calculating Absolute Drug Bioavailability.
    Jiang W; Yang JJ; Cao L; Xiao X; Shi XL; Cao YX
    J Pharm Pharm Sci; 2016; 19(2):181-7. PubMed ID: 27518168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose.
    Chow AT; Jusko WJ
    J Pharm Sci; 1990 Oct; 79(10):902-6. PubMed ID: 2280360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach to bioavailability testing: statistical method for comparing drug input calculated by a least-squares deconvolution technique.
    Pedersen PV
    J Pharm Sci; 1980 Mar; 69(3):318-24. PubMed ID: 7381709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.
    Rubin GM; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):437-50. PubMed ID: 6527233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical moments in pharmacokinetics.
    Yamaoka K; Nakagawa T; Uno T
    J Pharmacokinet Biopharm; 1978 Dec; 6(6):547-58. PubMed ID: 731417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean residence time of drugs administered non-instantaneously and undergoing linear tissue distribution and reversible metabolism and linear or non-linear elimination from the central compartment.
    Cheng H
    Biopharm Drug Dispos; 1995 May; 16(4):259-67. PubMed ID: 7548775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug absorption evaluation in the presence of changes in clearance: an algorithm and computer program for deconvolution with exact clearance correction.
    Veng-Pedersen P
    Biopharm Drug Dispos; 1987; 8(2):185-203. PubMed ID: 3593898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium antagonists. Pharmacokinetic properties.
    Kates RE
    Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of drugs with long elimination half-lives.
    Urso R; Aarons L
    Eur J Clin Pharmacol; 1983; 25(5):689-93. PubMed ID: 6141052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion: does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?
    Thompson GA; Toothaker RD
    Pharm Res; 2004 May; 21(5):781-4. PubMed ID: 15180334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. IV. Exact relationship between the terminal log-linear slope parameter beta and drug clearance.
    Veng-Pedersen P; Gillespie WR
    J Pharmacokinet Biopharm; 1987 Jun; 15(3):305-25. PubMed ID: 3668806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption.
    Deng J; Jhandey A; Zhu X; Yang Z; Yik KFP; Zuo Z; Lam TN
    PLoS One; 2018; 13(8):e0203361. PubMed ID: 30169515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of Laplace transform for the general disposition deconvolution equation in drug metabolism kinetics.
    Popović J
    Exp Toxicol Pathol; 1999 Jul; 51(4-5):409-11. PubMed ID: 10445406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.